Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TTK | P33981 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.47 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557196 | 1.00 | CYP1A2 (0.70) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| Methane SCHEMBL28143132 | 0.98 | CYP1A2 (0.68) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL31124675 | 0.85 | CYP1A2 (0.58) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL31539742 | 0.85 | CYP1A2 (0.53) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL6480580 | 0.83 | CYP1A2 (1.00) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| Tert-Butyl Formate SCHEMBL27819536 | 0.81 | CYP1A2 (0.54) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| Quinoline SCHEMBL27625393 | 0.81 | ALDH1A1 (0.53) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL1672674 | 0.75 | IDO1 (0.78) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL1411377 | 0.74 | KDM4E (0.56) | CYP1A2KDM4EGAAPDPK1CYP3A4 | |
| SCHEMBL27968550 | 0.74 | MKNK1 (0.71) | CYP1A2KDM4EGAAIDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1244 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115209883-B | Novel cell metabolism regulating compound and use thereof | 新月生物科学 | 2025-05-20 | — | — | CN | claimed |
| WO-2024193328-A1 | INDAZOLE SUBSTITUTED PODOPHYLLOTOXIN DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 汤亚杰 | 2024-09-26 | — | — | WO | claimed |
| CN-109180740-A | The aryl ruthenium complex and its preparation method and application for treating inflammation | 广西师范学院 | 2019-01-11 | — | — | CN | claimed |
| CN-108752389-A | Treat the aryl ruthenium complex and its preparation method and application of hypertension | 广西师范学院 | 2018-11-06 | — | — | CN | claimed |
| CN-108752391-A | Treat the aryl ruthenium complex and its preparation method and application of gastric cancer | 广西师范学院 | 2018-11-06 | — | — | CN | claimed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | claimed |
| CN-106588775-A | Indazole derivative as well as preparation method and application thereof | 南方医科大学 | 2017-04-26 | — | — | CN | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| CN-102898374-B | A kind of preparation method of 1H-indazole analog derivative | SHANGHAI BEPHARM CO., LTD. (CN) | 2016-03-23 | — | — | CN | claimed |
| CN-103787978-A | Synthesis method of 1-methylindazole-3-formic acid | ZHANGJIAGANG JIUMU TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | claimed |
| US-5500443-A | SCHIZOPHRENIA | ADIR ET COMPAGNIE (FR) | 1996-03-19 | — | — | US | claimed |
| WO-1996003437-A1 | PTH OR PTHrP ANTAGONISTS | SANDOZ LTD. (CH) | 1996-02-08 | — | — | WO | claimed |
| EP-0669331-A1 | Benzodioxane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1995-08-30 | — | — | EP | claimed |
| EP-0611375-A1 | PEPTIDES INHIBITING IL-1 BETA RELEASE | SANDOZ LTD. (CH) | 1994-08-24 | — | — | EP | claimed |
| WO-1993009135-A1 | PEPTIDES INHIBITING IL-1 BETA RELEASE | SANDOZ LTD. (CH) | 1993-05-13 | — | — | WO | claimed |
| US-4978603-A | Developing an emulsion layer containing a rhodium salt and a preferential grain size using a dihydroxy developer, a sulfite and an indazole compound | FUJI PHOTO FILM CO., LTD. (JP) | 1990-12-18 | — | — | US | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| EP-0186431-B1 | ANTI-HYPERTENSIVE OCTAHYDRO-6-AZAINDOLE DIPEPTIDE DERIVATIVES | Pfizer Limited (GB) | 1988-02-03 | — | — | EP | claimed |
| US-4711882-A | INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME; HYPOTENSIVE AND CARDIOTONIC AGENTS | PFIZER INC. (US) | 1987-12-08 | — | — | US | claimed |
| EP-0186431-A1 | Anti-hypertensive octahydro-6-azaindole dipeptide derivatives | Pfizer Limited (GB) | 1986-07-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | CYP1A2 2921/4885KDM4E 669/4885GAA 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.